前列腺特異性酸性磷酸酶抗體/PSAP Antibody |
|
|
產品名稱 ： 前列腺特異性酸性磷酸酶抗體/PSAP Antibody
產品類別 ： IVD診斷抗體原料
品 牌 ： GenomeMe
貨 號 ： IHC655
規(guī) 格 ： 0.1ml/1ml
|
|
詳細信息 |
|
|
純化方式 ：
緩 沖 液 ：
應用說明 ：
形 態(tài) ：
產品說明 ：
背景描述Description：
前列腺特異性酸性磷酸酶(PSAP)是在前列腺腺上皮中發(fā)現的一種前列腺酶。PSAP水平在前列腺增生和前列腺癌中升高，在轉移性前列腺癌中檢測到的水平最高。中度過表達PSAP也是骨病(如Paget病或甲狀旁腺功能亢進)、血細胞病(如鐮狀細胞病)、多發(fā)性骨髓瘤或溶酶體貯積性疾病(如高雪氏病)的特征。PSAP被認為比PSA更敏感，但特異性更低，然而，在適當的臨床環(huán)境下，抗PSAP可以作為抗PSA的有益補充。
Prostatic Specific Acid Phosphatase (PSAP) is a prostatic enzyme found in the glandular epithelium of the prostate. PSAP levels are elevated in hyperplastic prostate and prostate carcinoma, with the highest levels being detected in metastasized prostate cancer. Moderate overexpression of PSAP is also characteristic of diseases of the bone (such as Paget’s disease or hyperparathyroidism), diseases of blood cells (such as sickle-cell disease), multiple myeloma, or lysosomal storage diseases (such as Gaucher’s disease). PSAP is considered more sensitive, yet less specific, than PSA, however Anti-PSAP can act as a useful complement to Anti-PSA under suitable clinical contexts.
Specifications：
Clone： IHC655
Source： Mouse Monoclonal
Positive Control： Prostate, Prostate Adenocarcinoma
Dilution Range： 1:50-1:200
參考文獻References：
Ansari MA, et al. Am J Clin Path. 1981; 76:94-8.
Nadji M, et al. Ann N Y Acad Sci. 1982; 390:133-41.
Kimura N, et al. Virchows Arch A Pathol Anat Histopathol. 1986; 410:247-51.
Kidwai N, et al. Breast Cancer Res. 2004; 6:R18-23.
Kuroda N, et al. Pathol Int. 1999; 49:457-61.
Elgamal AA, et al. Urology. 1994; 44:84-90.
Gatalica Z, et al. Appl Immunohistochem Mol Morphol. 2000; 8:158-61.
Genega EM, et al. Mod Pathol. 2000; 13:1186-91.
Green LK, et al. Hum Pathol. 1991; 22:242-6.
Epstein JI. Urol Clin North Am. 1993; 20:757-70.
van Krieken JH. Am J Surg Pathol. 1993; 17:410-4.
|
|
| {返回} | |
| |||||||||||
